Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia’s GBMA Emphasizes Biosimilars Amid Government Change

Marks Final Biosimilar Awareness Week Under 2018 Education Grant

Executive Summary

As Australia’s GBMA launches its latest Biosimilars Awareness Week – the last under a five-year education grant – the association says it is looking forward to “the dawn of a new era” as it begins working with the newly-elected Labor government.

You may also be interested in...



GBMA Welcomes Australian Budget Co-Payment Commitment

The Australian government has committed to cutting co-payments for medicines listed on its pharmaceutical benefits scheme by 30%, a move which has been praised by the country’s Generic and Biosimilar Medicines Association.

Fresh Australian Industry Pact Will Insure Against Shortages

A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.

IGBA Raises Global Awareness With Biosimilars Week

A campaign aimed at raising awareness and educating international audiences about biosimilars will be run next week by the IGBA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel